Skip to main content
TSE:IN

InMed Pharmaceuticals Stock Forecast, Price & News

C$4.19
-0.07 (-1.64 %)
(As of 05/7/2021)
Add
Compare
Today's Range
C$4.13
C$4.27
50-Day Range
C$3.46
C$4.82
52-Week Range
C$3.35
C$13.70
Volume17,035 shs
Average Volume29,552 shs
Market CapitalizationC$33.73 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive IN News and Ratings via Email

Sign-up to receive the latest news and ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


About InMed Pharmaceuticals

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone604-669-7207
Employees4
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Cash FlowC$1.43 per share
Book ValueC$1.08 per share

Profitability

Debt

Price-To-Earnings

Miscellaneous

Market CapC$33.73 million
Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

0.64 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











InMed Pharmaceuticals (TSE:IN) Frequently Asked Questions

What stocks does MarketBeat like better than InMed Pharmaceuticals?

Wall Street analysts have given InMed Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but InMed Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How has InMed Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

InMed Pharmaceuticals' stock was trading at C$0.25 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, IN stock has increased by 1,576.0% and is now trading at C$4.19.
View which stocks have been most impacted by COVID-19
.

Who are InMed Pharmaceuticals' key executives?

InMed Pharmaceuticals' management team includes the following people:
  • Mr. Eric A. Adams, Pres, CEO & Director (Age 57, Pay $423.76k)
  • Mr. Bruce S. Colwill C.A., CPA, CA, CFO & Corp. Sec. (Age 56, Pay $313.13k)
  • Ms. Alexandra Diane-Janet Mancini, Sr. VP of Clinical & Regulatory Affairs (Age 68, Pay $308.19k)
  • Dr. Eric Chih-Hsien Hsu, Sr. VP of Preclinical R&D (Age 51, Pay $300.7k)
  • Mr. Michael Woudenberg P.Eng., VP of Chemistry, Manufacturing & Controls (Age 54, Pay $287.6k)
  • Dr. Sazzad Hossain, Co-Founder
  • Mr. Brendan Payne, Director of Investor Relations
  • Mr. Richard Hoy, VP of Sales & Marketing
  • Dr. Ado Muhammad, Sr. Consultant of Medical Affairs

Who are some of InMed Pharmaceuticals' key competitors?

What other stocks do shareholders of InMed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InMed Pharmaceuticals investors own include OrganiGram (OGI), Aurora Cannabis (ACB), Canopy Growth (WEED), Baidu (BIDU), Cara Therapeutics (CARA), Copper Mountain Mining (CMMC), Corbus Pharmaceuticals (CRBP), HEXO (HEXO), InMed Pharmaceuticals (IMLFF) and Immunomedics (IMMU).

What is InMed Pharmaceuticals' stock symbol?

InMed Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "IN."

How do I buy shares of InMed Pharmaceuticals?

Shares of IN and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is InMed Pharmaceuticals' stock price today?

One share of IN stock can currently be purchased for approximately C$4.19.

How much money does InMed Pharmaceuticals make?

InMed Pharmaceuticals has a market capitalization of C$33.73 million.

How many employees does InMed Pharmaceuticals have?

InMed Pharmaceuticals employs 4 workers across the globe.

What is InMed Pharmaceuticals' official website?

The official website for InMed Pharmaceuticals is www.inmedpharma.com.

How can I contact InMed Pharmaceuticals?

The company can be reached via phone at 604-669-7207.


This page was last updated on 5/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.